Cargando…

Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status

INTRODUCTION: Large cell neuroendocrine carcinomas (LCNEC) are a group of rare high grade neuroendocrine tumors that often behave clinically like small cell carcinoma (SCLC) and are treated as such. No major advancement in the management of these tumors has occurred in the last 30 years. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chauhan, Aman, Arnold, Susanne M., Kolesar, Jill, Thomas, Hala Elnakat, Evers, Mark, Anthony, Lowell
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865703/ https://www.ncbi.nlm.nih.gov/pubmed/29581877 http://dx.doi.org/10.18632/oncotarget.24553

Ejemplares similares

Gynecologic large cell neuroendocrine carcinoma: A review
por: Burkeen, Grant, et al.
Publicado: (2020)

Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature
por: Chauhan, Aman, et al.
Publicado: (2017)

Biliary tract large cell neuroendocrine carcinoma: current evidence
por: Raiker, Riva, et al.
Publicado: (2019)

Management of Large Cell Neuroendocrine Carcinoma
por: Corbett, Virginia, et al.
Publicado: (2021)

hPG(80) (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors
por: Chauhan, Aman, et al.
Publicado: (2022)

Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry
por: Jacob, Aasems, et al.
Publicado: (2021)

Global burden of neuroendocrine tumors and changing incidence in Kentucky
por: Chauhan, Aman, et al.
Publicado: (2018)

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary
por: Chauhan, Aman, et al.
Publicado: (2018)

Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma
por: Shi, Zheng, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
por: Gubbi, Sriram, et al.
Publicado: (2022)

Integrating a 92-Gene Expression Analysis for the Management of Neuroendocrine Tumors of Unknown Primary
por: Chauhan, Aman, et al.
Publicado: (2019)

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
por: Kim, Bum Jun, et al.
Publicado: (2017)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors
por: Chow, Zeta, et al.
Publicado: (2021)

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
por: Federico, Piera, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches
por: Batista-Duharte, Alexander, et al.
Publicado: (2022)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

Immune checkpoint inhibitors in cervical cancer: Current status and research progress
por: Xie, Yunkai, et al.
Publicado: (2022)

The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity
por: Xing, Hui, et al.
Publicado: (2023)

Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: A retrospective analysis in neuroendocrine tumor patients
por: Chauhan, Aman, et al.
Publicado: (2020)

Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers
por: Eso, Yuji, et al.
Publicado: (2020)

The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review
por: Brahm, Cyrillo G., et al.
Publicado: (2020)

Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors
por: Cheng, Yue, et al.
Publicado: (2023)

What is the role of checkpoint inhibitors in neuroendocrine neoplasms?
por: Al-Toubah, Taymeyah, et al.
Publicado: (2020)

Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer
por: Lim, Sung Won, et al.
Publicado: (2019)

Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer
por: Kang, Byung Woog, et al.
Publicado: (2020)

Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden
por: Wang, Victoria E., et al.
Publicado: (2017)

Mechanisms of immune evasion and current status of checkpoint inhibitors in non‐small cell lung cancer
por: Qin, Angel, et al.
Publicado: (2016)

Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known
por: Zheng, Caiyun, et al.
Publicado: (2023)

Neuroendocrine Tumors in Pediatrics
por: Farooqui, Zainab Azam, et al.
Publicado: (2019)

Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients?
por: Chauhan, Aman, et al.
Publicado: (2021)

Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell Neuroendocrine Carcinoma
por: Saghaeiannejad Esfahani, Hoda, et al.
Publicado: (2021)

Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive System
por: Xing, Jiazhang, et al.
Publicado: (2020)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
por: Bongiovanni, Alberto, et al.
Publicado: (2021)

Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary
por: Hendifar, Andrew E., et al.
Publicado: (2019)

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives
por: Welti, Michèle, et al.
Publicado: (2022)

Enhanced Efficacy of Chemotherapy by Addition of Immune Checkpoint Inhibitors in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung: A Real-World Analysis
por: Meng, Lingbin, et al.
Publicado: (2023)

Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma
por: Zeng, Zhu, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n5o75o6s5jcjd3a4ed9dljqsle